Literature DB >> 33572385

Management of Lupus Nephritis.

Farah Tamirou1, Frédéric A Houssiau1.   

Abstract

Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials.

Entities:  

Keywords:  combination therapy; lupus nephritis; repeat kidney biopsy; treat-to-target approach

Year:  2021        PMID: 33572385      PMCID: PMC7916202          DOI: 10.3390/jcm10040670

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  64 in total

1.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

2.  Belimumab may not prevent lupus nephritis in serologically active patients with ongoing non-renal disease activity.

Authors:  C Sjöwall; L Cöster
Journal:  Scand J Rheumatol       Date:  2014-04-02       Impact factor: 3.641

3.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Authors:  Richard Furie; Michelle Petri; Omid Zamani; Ricard Cervera; Daniel J Wallace; Dana Tegzová; Jorge Sanchez-Guerrero; Andreas Schwarting; Joan T Merrill; W Winn Chatham; William Stohl; Ellen M Ginzler; Douglas R Hough; Z John Zhong; William Freimuth; Ronald F van Vollenhoven
Journal:  Arthritis Rheum       Date:  2011-12

4.  Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.

Authors:  Christine Hsieh; Anthony Chang; Daniel Brandt; Riteesha Guttikonda; Tammy O Utset; Marcus R Clark
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-06       Impact factor: 4.794

5.  Urinary proteomics revealed prostaglandin H(2)D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis.

Authors:  Poorichaya Somparn; Nattiya Hirankarn; Asada Leelahavanichkul; Weerapan Khovidhunkit; Visith Thongboonkerd; Yingyos Avihingsanon
Journal:  J Proteomics       Date:  2012-03-30       Impact factor: 4.044

6.  Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.

Authors:  Richard Furie; Brad H Rovin; Frédéric Houssiau; Ana Malvar; Y K Onno Teng; Gabriel Contreras; Zahir Amoura; Xueqing Yu; Chi-Chiu Mok; Mittermayer B Santiago; Amit Saxena; Yulia Green; Beulah Ji; Christi Kleoudis; Susan W Burriss; Carly Barnett; David A Roth
Journal:  N Engl J Med       Date:  2020-09-17       Impact factor: 91.245

7.  Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort.

Authors:  J Vandepapelière; S Aydin; J-P Cosyns; G Depresseux; M Jadoul; F A Houssiau
Journal:  Lupus       Date:  2013-12-03       Impact factor: 2.911

8.  A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial.

Authors:  Farah Tamirou; Bernard R Lauwerys; Maria Dall'Era; Meggan Mackay; Brad Rovin; Ricard Cervera; Frédéric A Houssiau
Journal:  Lupus Sci Med       Date:  2015-11-12

9.  De novo lupus nephritis during treatment with belimumab.

Authors:  Ioannis Parodis; Edward M Vital; Sabih-Ul Hassan; Andreas Jönsen; Anders A Bengtsson; Per Eriksson; Dag Leonard; Iva Gunnarsson; Lars Rönnblom; Christopher Sjöwall
Journal:  Rheumatology (Oxford)       Date:  2021-09-01       Impact factor: 7.046

10.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Authors:  Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2009-09-28       Impact factor: 5.156

View more
  2 in total

Review 1.  Belimumab for systemic lupus erythematosus - Focus on lupus nephritis.

Authors:  Marlene Plüß; Silvia Piantoni; Björn Tampe; Alfred H J Kim; Peter Korsten
Journal:  Hum Vaccin Immunother       Date:  2022-05-19       Impact factor: 4.526

2.  Anxiety and depression prevalence and their risk factors in lupus nephritis patients: A case-control study.

Authors:  Ying Hu; Ge Zhan
Journal:  Immun Inflamm Dis       Date:  2022-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.